real-world validation of the value of the ipss-m for prognostication in patients with mds
Published 1 year ago • 58 plays • Length 3:35Download video MP4
Download video MP3
Similar videos
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
3:21
real-world safety analysis of deferiprone in patients with mds
-
1:59
real-world outcomes of ide-cel in heavily pre-treated r/r mm
-
7:09
the role of real-world evidence in the evaluation of new drugs
-
2:10
drd versus vrd in patients with mm: a real-world retrospective analysis
-
1:16
state of the art: mds
-
1:27
the real world utilization of mrd in myeloma across europe
-
3:46
variant allele frequency in patients with sf3b1-mutated mds
-
1:04
the future of mds management
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:23
the significance of variant allele frequency in patients with sf3b1-mutated mds
-
2:04
state-of-the-art treatment for hr-mds
-
2:48
how can mutational screening guide current clinical practice in mds?
-
6:31
the importance of patient perspectives and real-world data
-
0:32
the importance of obtaining real-world data
-
2:16
current and future treatment approaches for hr-mds
-
1:33
real-world comparison of d-rvd and rvd induction in patients with newly diagnosed multiple myeloma
-
1:06
the current state of the art in hr-mds and the need to improve treatment approaches
-
2:10
updated overall survival data on eltanexor for hma-refractory mds